Immunotherapy for platinum-resistant ovarian, with tumor testing
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 2 study tests an immunotherapy approach for women whose high-grade serous ovarian cancer came back within 6 months of platinum chemotherapy. It may help shrink tumors and improve control of the disease, but you’ll need tumor biopsies and lab/heart/lung checks to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-grade serous ovarian cancer (or fallopian tube or peritoneal cancer) that progressed within 6 months of your last platinum chemotherapy
- Your original tumor has been confirmed under a microscope (histology) and you have measurable tumor spots on scans or exam
- You can have tumor biopsies before treatment and during treatment, from at least one spot your team can safely biopsy, and you agree to consent
- You’re generally well enough for treatment (age 18+, life expectancy about 3 months or more, and good basic activity level)
- Your recent treatments and side effects fit the trial timing rules (at least 4 weeks since last treatment, and prior side effects must be mostly resolved)
- Your blood counts and organ/liver/kidney function meet required lab levels, and your heart/lung safety checks are acceptable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This trial tests a combination treatment for advanced ovarian cancer that hasn't been treated before. It combines chemotherapy, a personalized vaccine made from your own immune cells, and a drug called pembrolizumab to help your immune system fight the cancer.
This study tests a new combination treatment (ubamatamab plus another drug) for people with ovarian cancer that no longer responds to platinum chemotherapy. It could be an option if your cancer has kept growing despite prior treatment.
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
This trial tests a new combination of drugs for ovarian cancer that has come back quickly after platinum-based chemo. The goal is to see if adding an immunotherapy and a targeted pill to non-platinum chemo can help shrink tumors.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.